ICER Report Evaluates Clinical Value of New Narcolepsy Type 1 Treatment

The Institute for Clinical and Economic Review (ICER) has released a comprehensive assessment of oveporexton, an investigational oral therapy for narcolepsy type 1 (NT1). The drug, developed by Takeda, is the first in its class to target the orexin receptor 2, addressing the underlying cause of NT1. ICER’s report, published in June 2026, evaluates the drug’s clinical effectiveness and economic value, with oveporexton receiving FDA approval in August 2026. ## Clinical Effectiveness and Evidence Ratings ICER’s analysis found that oveporexton demonstrated moderate certainty of a small or substantial net health benefit when compared to no pharmacological treatment, earning a B+ evidence rating. The drug also showed comparable or superior benefits to existing treatments such as modafinil, armodafinil, venlafaxine, sodium oxybates, and pitolisant, resulting in a C++ rating. These findings suggest that oveporexton may offer better health outcomes than current options for NT1 patients. Foluso Agboola, MBBS, MPH, senior vice president of research at ICER, highlighted the significance of the drug’s novel mechanism. In a statement, Agboola noted that while existing narcolepsy treatments are costly and often provide incomplete relief, oveporexton’s ability to directly target the root cause of NT1 could improve wakefulness and quality of life for patients. The report emphasizes the importance of value-based pricing to ensure affordability and access. ## Pricing and Access Recommendations Although the manufacturer has not yet disclosed a US price for oveporexton, ICER calculated a health benefit price benchmark ranging from $50,400 to $59,400 per year. Pricing within this range would allow all eligible patients to receive treatment without exceeding budget impact thresholds. The report also includes recommendations from a policy roundtable involving clinical experts, patients, payers, and the manufacturer. Key takeaways from the roundtable include: - **Affordability and Access:** Manufacturers should align drug prices with the therapeutic value to ensure affordability and broad patient access. - **Step Therapy Concerns:** If priced according to its value, payers should avoid imposing step therapy requirements, as oveporexton’s unique mechanism of action justifies unrestricted access. - **Patient Advocacy:** Patient organizations play a crucial role in advocating for fair pricing and appropriate insurance coverage across the healthcare system. The report underscores the potential of oveporexton to transform NT1 treatment while calling for responsible pricing to balance innovation with accessibility.